QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.000737v1 32/10/1178    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murata, D. Articles by Sasaki, T. Search for Related Content PubMed PubMed Citation Articles by Murata, D. Articles by Sasaki, T.

A CRUCIAL ROLE OF URIDINE/CYTIDINE KINASE 2 IN ANTITUMOR ACTIVITY OF 3'-ETHYNYL NUCLEOSIDES

Department of Experimental Therapeutics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan (D.M., Y.E., T.O., Y.S., M.K., T.S.); Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan (K.S.); and Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan (A.M.)

The antitumor 3'-ethynyl nucleosides, 1-(3-C-ethynyl-ß-D-ribopentofuranosyl)cytosine (ECyd) and 1-(3-C-ethynyl-ß-D-ribopentofuranosyl)uridine (EUrd), are potent inhibitors of RNA polymerases and show excellent antitumor activity against various human solid tumors in xenograft models. ECyd is being investigated in phase I clinical trials as a novel anticancer drug possessing a unique antitumor action. ECyd and EUrd require the activity of uridine/cytidine kinase (UCK) to produce the corresponding active metabolite. The UCK family consists of two members, UCK1 and UCK2, and both UCKs are expressed in many tumor cells. It was unclear, however, whether UCK1 or UCK2 is responsible for the phosphorylation of the 3'-ethynyl nucleosides. We therefore established cell lines that are highly resistant to the 3'-ethynyl nucleosides from human fibrosarcoma HT-1080 and gastric carcinoma NUGC-3. All the resistant cell lines showed a high cross-resistance to ECyd and EUrd. As a result of cDNA sequence analysis, we found that UCK2 mRNA expressed in EUrd-resistant HT-1080 cells has a 98-base pair deletion of exon 5, whereas EUrd-resistant NUGC-3 cells were harboring the point mutation at nucleotide position 484 (C to T) within exon 4 of UCK2 mRNA. This mutation was confirmed by genome sequence analysis of the UCK2 gene. Moreover, the expression of UCK2 protein was decreased in these resistant cells. In contrast, no mutation in the mRNA or differences in protein expression levels of UCK1 were shown in the EUrd-resistant HT-1080 and NUGC-3 cells. These results suggest that UCK2 is responsible for the phosphorylation and activation of the antitumor 3'-ethynyl nucleosides.

This article has been cited by other articles:

				B. D. Zlatopolskiy, A. Morgenroth, F. H.-G. Kunkel, E. A. Urusova, C. Dinger, T. Kull, C. Lepping, and S. N. Reske Synthesis and Biologic Study of IV-14, a New Ribonucleoside Radiotracer for Tumor Visualization J. Nucl. Med., November 1, 2009; 50(11): 1895 - 1903. [Abstract] [Full Text] [PDF]